Ivabradine in Cirrhotic Cardiomyopathy

NARecruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

October 31, 2024

Study Completion Date

December 31, 2024

Conditions
Cirrhotic CardiomyopathyLeft Ventricular DysfunctionCirrhosis, LiverPortal Hypertension
Interventions
DRUG

Betablocker + ivabradine

Use of maximum tolerated dose of carvedilol and ivabradine to achieve therapeutic heart rate reduction (THR) to 55-65 beats per minute

DRUG

Betablocker

Use of maximum tolerated dose of carvedilol to achieve targeted heart rate reduction (THR) to 55-65 beats per minute (responder) or inability to reach THR (non responder) with maximum dose of carvedilol, maintaining a minimum MAP of 70 mmHg.

Trial Locations (1)

160012

RECRUITING

Postgraduate Institute of Medical Education and Research, Chandigarh

All Listed Sponsors
lead

Post Graduate Institute of Medical Education and Research, Chandigarh

OTHER